135680-03-4

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 101-77-9 4,4'-diamino diphenyl methane 
• 74651-77-7 2-(tert-butoxycarbonyloxyimino)-2-phenylacetonitrile 

Downstream Products

• 1196966-32-1 N,N'-di(tert-butoxycarbonyl)-N''-[4-(4-tert-butoxycarbonylaminobenzyl)phenyl]guanidine 
• 1196966-39-8 2-[4-(4-tert-butoxycarbonylaminobenzyl)phenylimino]imidazolidine-1,3-dicarboxylic acid di-tert-butyl ester 
• 1283594-44-4 N-{4-[4-(2-bromoacetylamino)benzyl]phenyl}carbamic acid 1,1-dimethylethyl ester 
• 1283595-20-9 N-{4-[4-({2-[(3S)-3-hydroxy-1-pyrrolidinyl]acetyl}amino)benzyl]phenyl}-2-(1-pyrrolidinyl)acetamide 
• 1283595-17-4 N-{4-[4-({2-[(3R)-3-hydroxy-1-pyrrolidinyl]acetyl}amino)benzyl]phenyl}-2-(1-pyrrolidinyl)acetamide 
• 1283595-14-1 N-{4-[4-({2-[(2R)-2-(hydroxymethyl)1-pyrrolidinyl]acetyl}amino)benzyl]phenyl}-2-(1-pyrrolidinyl)acetamide 
• 1283595-11-8 N-{4-[4-({2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]acetyl}amino)benzyl]phenyl}-2-(1-pyrrolidinyl)acetamide 
• 1283595-09-4 N-[4-(4-{[2-(4-morpholinyl)acetyl]amino}benzyl)phenyl]-2-(1-pyrrolidinyl)acetamide 
• 1283595-07-2 N-[4-(4-{[2-(1-piperidinyl)acetyl]amino}benzyl)phenyl]-2-(1-pyrrolidinyl)acetamide 
• 1283594-57-9 N-(4-{4-[(2-aminoacetyl)amino]benzyl}phenyl)-2-(1-pyrrolidinyl)acetamide 
• 1283594-54-6 N-[2-oxo-2-(4-{4-[2-(1-pyrrolidinyl)acetylamino]benzyl}phenylamino)ethyl]carbamic acid 1,1-dimethylethyl ester 
• 1283594-51-3 N-{4-[4-(acetylamino)benzyl]phenyl}-2-(1-pyrrolidinyl)acetamide 
• 1283594-49-9 N-[4-(4-aminobenzyl)phenyl]-2-(1-pyrrolidinyl)acetamide 
• 1283594-47-7 N-(4-{4-[2-(1-pyrrolidinyl)acetylamino]benzyl}phenyl)carbamic acid 1,1-dimethylethyl ester 

Relevant academic research and scientific papers

INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS

This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases, other than cancer and proteolytic enzyme mediated diseases, other than cancer, and pharmaceutical compositions for use in such therapy.

RADIATION-SENSITIVE RESIN COMPOSITION, METHOD FOR FORMING A RESIST PATTERN, COMPOUND, AND POLYMER

A radiation-sensitive resin composition includes a first polymer that includes a repeating unit having an acid-labile group and becomes alkali-soluble upon dissociation of the acid-labile group, and a radiation-sensitive acid-generating agent. The acid-labile group has a structure shown by a general formula (1). R1 represents a methyl group or the like, R2 represents a hydrocarbon group that forms a cyclic structure, R3 represents a fluorine atom or the like, R4 represents a carbon atom, and n1 is an integer from 1 to 7.

An efficient and highly chemoselective N-Boc protection of amines, amino acids, and peptides under heterogeneous conditions

A simple and efficient procedure for chemoselective mono-N-Boc protection of various structurally diverse amines, amino acids, and peptides with di-tert-butyl dicarbonate using Amberlyst-15 as catalyst in ethanol is described. The catalyst can be readily separated from the reaction products with simple filtration and recovered for direct reuse. No competitive side-reactions such as formation of isocyanate, urea, oxazolidinone, and N,N-di-Boc derivatives were observed.

Synthesis of GN8 derivatives and evaluation of their antiprion activity in TSE-infected cells

A series of GN8 derivatives were synthesized from various diamines, carboxylic acid derivatives, and nitrogen nucleophiles, and their antiprion activity was tested in TSE-infected mouse neuronal cells. We found that two ethylenediamine units, hydrophobic substituents on the nitrogen atoms, and the diphenylmethane scaffold were essential structural features responsible for the activity. Seven derivatives bearing substituents at the benzylic position exhibited an improved antiprion activity with the IC50 values of 0.51-0.83 μM. Conformational analysis of model compounds suggested that the introduction of the substituent at the benzylic position restricted the conformational variability of the diphenylmethane unit.

Asymmetrical diaromatic guanidinium/2-aminoimidazolinium derivatives: Synthesis and DNA affinity

In this paper we report the synthesis of three families of new amidine-based aromatic derivatives as potential DNA minor groove binding agents for the treatment of cancer. The preparation of monoguanidine, mono-2-aminoimidazoline, and asymmetric diphenylg

Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas

This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS

Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se.

Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas

This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

INHIBITION OF RAF KINASE USING QUINOLYL, ISOQUINOLYL OR PYRIDYL UREAS

This invention relates to a group of quinolyl, isoquinolyl and pyridyl ureas, their the use in treating raf mediated diseases, and pharmaceutical compositions which contain these ureas for use in such therapy.